Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
Public ClinicalTrials.gov record NCT01643928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.
Study identification
- NCT ID
- NCT01643928
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- Rituximab-Pfizer (PF-05280586) x 3 courses Biological
- Rituximab-EU+ Rituximab-Pfizer x 2 Courses Biological
- Rituximab-US + Rituximab-Pfizer x 2 Courses Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 15, 2012
- Primary completion
- Mar 13, 2016
- Completion
- Mar 13, 2016
- Last update posted
- Jan 28, 2019
2012 – 2016
United States locations
- U.S. sites
- 34
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Rheumatology Associates of North Alabama, PC | Huntsville | Alabama | 35801 | — |
| Arthrocare, Arthritiscare & Research, PC | Gilbert | Arizona | 85234 | — |
| CHI St. Vincent Medical Group Hot Springs | Hot Springs | Arkansas | 71913 | — |
| UCLA Clinical & Translational Research Center | Los Angeles | California | 90095 | — |
| UCLA David Geffen School of Medicine | Los Angeles | California | 90095 | — |
| Desert Medical Advances | Palm Desert | California | 92260 | — |
| New England Research Associates, LLC | Trumbull | Connecticut | 06611 | — |
| QPS Labs | Newark | Delaware | 19711 | — |
| University of South Florida - College of Medicine Carol and Frank Morsani Center | Tampa | Florida | 33612 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Illnois Bone & Joint Institute | Morton Grove | Illinois | 60053 | — |
| Covance Central Laboratory Services | Indianapolis | Indiana | 46214 | — |
| Bluegrass Community Research, Inc. | Lexington | Kentucky | 40504 | — |
| Klein & Associates, M.D., P.A. | Cumberland | Maryland | 21502 | — |
| Clinical Pharmacology Study Group | Worcester | Massachusetts | 01605 | — |
| Bronson Internal Medicine and Rheumatology | Battle Creek | Michigan | 49015 | — |
| Justus J. Fiechtner, MD, PC | Lansing | Michigan | 48910 | — |
| University of Nevada School of Medicine | Las Vegas | Nevada | 89102 | — |
| Dartmouth - Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| North Shore-LIJ Health System - Division of Rheumatology and Allergy-Clinical | Great Neck | New York | 11021 | — |
| PMG Research of Hickory LLC | Hickory | North Carolina | 28602 | — |
| PMG Research of Hickory, LLC | Hickory | North Carolina | 28602 | — |
| Cincinnati Rheumatic Disease Study Group | Cincinnati | Ohio | 45219 | — |
| Health Research of Oklahoma | Oklahoma City | Oklahoma | 73103 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| The Arthritis Group | Philadelphia | Pennsylvania | 19152 | — |
| Clinical Research Center of Reading, LLC | Wyomissing | Pennsylvania | 19610 | — |
| Arthritis Associates, PLLC | Hixson | Tennessee | 37343 | — |
| Arthritis Clinic | Jackson | Tennessee | 38305 | — |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | — |
| Metroplex Clinical Research Center | Dallas | Texas | 75231 | — |
| Apocell, Inc | Houston | Texas | 77054 | — |
| Southwest Rheumatology Research, LLC | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01643928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2019 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01643928 live on ClinicalTrials.gov.